Centrally active nonhormonal hot flash therapies.

Abstract

Given the problems associated with hormonal therapy, and the prominent problem of hot flashes in menopausal women, there is a need for nonhormonal agents to alleviate hot flashes. Several compounds that appear to act on the central nervous system have been investigated. Potential mechanisms for their effects on hot flashes have been described. Bellergal (no longer available on the US market, where it was known as Bellergal-S), a combination preparation sedative that consists of low-dose phenobarbital, ergotamine tartrate, and levorotatory alkaloids of belladonna, is an old agent that was popular approximately 20 years ago; however, there is limited suggestion of efficacy for this agent. Clonidine, an older antihypertensive drug, is another centrally active agent that has been studied. Randomized trials have demonstrated that it clearly works for reducing hot flashes, but the magnitude of efficacy is somewhat limited. Toxicity from this agent limits its utility in the clinic. Methyldopa is another centrally active agent that has been studied but to a more limited degree. It appears to have minimal efficacy and too much toxicity to make it clinically useful. Anecdotal observations from a number of sources suggested that newer antidepressants can alleviate hot flashes. This led to pilot trials of venlafaxine and paroxetine, with results suggesting benefit from both drugs. Subsequently, randomized, placebo-controlled, double-blind clinical trials of venlafaxine, paroxetine, and fluoxetine were conducted. All 3 of these clinical trials demonstrated statistically significant reductions in hot flashes with these newer antidepressants compared with placebo. Pilot trials of citalopram and mirtazapine, 2 other newer antidepressants, have also suggested efficacy. Toxicity evaluations have suggested that these agents are, again, well tolerated by the majority of patients. A recent trial, however, was unable to demonstrate any benefit for fluoxetine or citalopram over a placebo. Anecdotal observations also suggested that gabapentin was helpful for alleviating hot flashes. This led to pilot trials that again suggested efficacy. Subsequently, 2 large placebo-controlled, randomized, double-blind clinical trials were conducted. Both of these demonstrated statistically significant efficacy for gabapentin compared with a placebo. This drug is relatively well tolerated by most patients. Thus, centrally active nonhormonal agents clearly do decrease hot flashes in women. The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing.

• Authors: Charles L Loprinzi, Vered Stearns, Debra Barton
• Journal: The American journal of medicine (Am J Med) Vol. 118 Suppl 12B Pg. 118-23 (Dec 19 2005) ISSN: 1555-7162 [Electronic] United States
• PMID: 16414336 (Publication Type: Consensus Development Conference, NIH, Journal Article)

Chemical References

• Amines
• Antidepressive Agents
• Antihypertensive Agents
• Belladonna Alkaloids
• Cyclohexanecarboxylic Acids
• Drug Combinations
• Ergotamines
• belladonna alkaloid, ergotamine, phenobarbital drug combination
• gamma-Aminobutyric Acid
• Methyldopa
• Gabapentin
• Clonidine
• Methysergide
• Phenobarbital

Topics

• Amines (therapeutic use)
• Antidepressive Agents (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Belladonna Alkaloids
• Clonidine (therapeutic use)
• Cyclohexanecarboxylic Acids (therapeutic use)
• Drug Combinations
• Ergotamines (therapeutic use)
• Female
• Gabapentin
• Hot Flashes (drug therapy, etiology)
• Humans
• Menopause (physiology)
• Methyldopa (therapeutic use)
• Methysergide (therapeutic use)
• Phenobarbital (therapeutic use)
• gamma-Aminobutyric Acid (therapeutic use)